

30 November 2023

Our Ref: RFI 54714

Dear

**Freedom of Information Act 2000
Information in Relation to Treatments for Inflammatory Diseases.**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 17 November 2023.

A response to each of the questions raised has been provided by the Surgery, Elective Care, Maternity & Paediatrics Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

**Caroline Degans
Information Governance Officer**

Q1. How many patients were treated with the following drugs from the following departments (for any disease) in the 3 months between the start of Aug 2023 and the end of Oct 2023?

Please use the latest available 3 months if August to October is not available and specify which 3 months has been used.

- A1. Please see Table 1 below for the number of patients who were treated with the following drugs, in all sites within the Trust for the period 01/08/2023 to 31/10/2023.

Table 1

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)	2	8	64
Adalimumab (Biosimilars)	127	233	377
Apremilast	Nil	Nil	2
Bimekizumab	Nil	Nil	Nil
Brodalumab	2	Nil	Nil
Certolizumab Pegol	8	Nil	20
Deucravacitinib	Nil	Nil	Nil
Etanercept (Enbrel)	Nil	Nil	38
Etanercept (Biosimilars)	3	Nil	161
Guselkumab	31	Nil	2
Infliximab (Remicade)	3	4	4
Infliximab (Biosimilars)	7	260	9
Ixekizumab	15	Nil	20
Risankizumab	69	1	Nil
Secukinumab	25	Nil	69
Tildrakizumab	Nil	Nil	Nil
Ustekinumab	22	170	4
Upadacitinib	4	9	8
Vedolizumab	Nil	121	Nil
Filgotinib	1	16	Nil
Golimumab	Nil	3	83
Mirikizumab	Nil	Nil	Nil
Ozanimod	Nil	2	Nil
Tofacitinib	Nil	4	2
Abatacept	Nil	Nil	39
Baricitinib	1	Nil	26
Rituximab	Nil	Nil	20
Sarilumab	Nil	Nil	3
Tocilizumab	Nil	Nil	80